endometrial sarcoma
Recently Published Documents


TOTAL DOCUMENTS

55
(FIVE YEARS 10)

H-INDEX

11
(FIVE YEARS 1)

Author(s):  
Negin Sadeghi ◽  
Susan Addley ◽  
Moiad Alazzam ◽  
Zoe Traill ◽  
Catherine A. Johnson ◽  
...  

2021 ◽  
pp. 868-873
Author(s):  
Rim Abou Chakra ◽  
Bernard Najib ◽  
Wael Abdallah ◽  
Mira Akiki ◽  
Lea El Khoury ◽  
...  

B-cell lymphoblastic lymphoma (LBL) is a highly aggressive malignant proliferation of lymphoblasts of B-origin grouped with acute lymphoblastic leukemia. Multiple studies demonstrated the various sites of involvement in adult LBL. The involvement of the uterus as a site of relapse for such disease is rare. We herein report the case of relapsed B-cell LBL mimicking endometrial sarcoma. The patient is a 56-year-old female patient known to have B-cell LBL on chemotherapy. She presented with abdominal pain and fever. Positron emission tomodensitometry-computed tomography showed the presence of a uterine mass with bilateral iliac lymph node involvement. She underwent surgery with mass removal and pathology showed relapsed B-cell LBL.


2021 ◽  
pp. 60-61
Author(s):  
JC Sharma ◽  
Anupma Anupma ◽  
Basanti Mazumdar ◽  
Dhruba Banik ◽  
Avir Sarkar

Undifferentiated endometrial sarcoma is a rare uterine malignancy of mesodermal origin. Only a few cases have been reported in literature. Herein, we describe a 56-year old woman who presented with post-menopausal bleeding of a short duration. Endometrial curettings were suggestive of undifferentiated sarcoma. Computed tomography showed an enlarged uterus with welldened mass in the endometrial cavity extending down to the cervix. A total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic and para-aortic lymphadenectomy and omental biopsies were taken. Histological examination revealed a tumour with a permeative growth pattern composed of uniformly high grade round tumour cells with high mitotic activity. However, there was no lymphovascular space invasion. Tumour cells were strongly positive for CD10 signifying high grade endometrial stromal sarcoma (HG-ESS). Post R0 resection, patient is now receiving adjuvant chemotherapy. However, it is seen that most patients have early recurrence following even R0 resection.


2021 ◽  
pp. 014556132098394
Author(s):  
John S. Levinson ◽  
Paris J. Austell ◽  
Max A. Plitt ◽  
Ritu Ghai ◽  
Paolo Gattuso ◽  
...  

Metastatic skull base malignancies infrequently occur but, when present, typically arise from breast malignancies. Pterygopalatine fossa (PPF) metastasis of any malignancy is further seldom reported, and metastasis of gynecologic malignancies to the PPF has not been previously described in the literature. We present a single case of a 42-year-old female with the first likely case of high-grade endometrial sarcoma metastatic to the PPF. The patient presented with facial pain and numbness in the V2 distribution presented for evaluation. History was significant for several months of dysmenorrhea and metrorrhagia. Computed tomography, magnetic resonance imaging, and positron emission tomography imaging revealed a PPF mass with local extension and bony metastases. Endoscopic biopsy was performed, and final pathology was most consistent with metastatic high-grade endometrial stromal sarcoma. This is the first reported case of likely metastatic endometrial sarcoma to the PPF. This case report highlights the possibility of rare distant metastasis of gynecologic malignancy to this area of the skull base.


Author(s):  
Salah Berkane

Introduction: Endometrial sarcoma is a rare condition, affecting women in their 60s. If total hysterectomy associated with bilateral adnexectomy is the standard treatment and can control the disease when it is localized in the uterus, at the peritoneal localization stage its prognosis becomes more negative with reduced possibilities of resection and overall survival at 5 years, therefore, the same with rates close to 30%. We report two cases of endometrial sarcoma with peritoneal localizations managed with a multidisciplinary approach and in several steps or multimodal approach associating a cytoreduction preceded or associated with systemic chemotherapy and intraperitoneal chemotherapy. These two advanced tumours were cured with this approach and at the final step, no deposit tumor were present. The global survival is respectively of 28 months and 63 months. Conclusion: this approach seems to be efficient in front of the advanced stage of endometrial sarcoma and we think that it must be adopted for a great number of patients to improve the survival and quality of life.


2020 ◽  
Vol 41 (24) ◽  
pp. 2338-2338
Author(s):  
Fan Yang ◽  
Xiaojun Xie ◽  
Fengxu Yu ◽  
Mingbin Deng

Rare Tumors ◽  
2020 ◽  
Vol 12 ◽  
pp. 203636132097286 ◽  
Author(s):  
Angela Duvalyan ◽  
Kirk Tran ◽  
Christopher Lee ◽  
Shefali Chopra ◽  
James Hu

Endometrial stromal sarcomas (ESS) account for 10-15% of uterine malignancies and are classified into four categories: endometrial stromal nodule (ESN), low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS) and undifferentiated uterine sarcoma (USS). Depending on stage, ESS is treated with surgery, hormone therapy, chemotherapy or targeted therapy. A rare complication of ESS with metastatic pulmonary disease is recurrent, bilateral pneumothoraces. The current literature has reported on patients with ESS who either presented with pneumothoraces at their initial diagnosis, and thus were untreated, or after treatment with surgical resection and hormone therapy. There have been no case reports of patients with ESS who presented with pneumothoraces while receiving chemotherapy. Furthermore, there have been no reported cases of patients with HG-ESS presenting with this rare complication. We would like to expand the literature by reporting on two patients with HG-ESS who presented with pneumothoraces while concurrently receiving chemotherapy.


Sign in / Sign up

Export Citation Format

Share Document